Clinicopathologic features of triple negative breast cancers: An experience from Pakistan

Diagnostic Pathology

Volumn 9, Issue 1, 2014, Pages

  Hashmi, Atif A ^a   Edhi, Muhammad M ^a   Naqvi, Hanna ^a   Faridi, Naveen ^a   Khurshid, Amna ^a   Khan, Mehmood ^b  

^a CIVIL HOSPITAL   (Pakistan)

^b DHAKA MEDICAL COLLEGE   (Bangladesh)

Author keywords

Basal breast cancer; ER; Her2neu; PR; Triple negative breast cancer

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PAKISTAN; PATHOLOGY; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PAKISTAN; RETROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899472355     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-9-43     Document Type: Article

References (54)

1. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
2. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167. doi:10.1200/JCO.2008.18.1370, 10.1200/JCO.2008.18.1370, 2667820, 19204204.
3. Moldovan L, Mitroi A, Petrescu CM, Aschie M. Classification of breast carcinomas according to gene expression profiles. J Med Life 2013, 6(1):14-17. 3624639, 23599813.
4. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol 2005, 23:7350-7360. 10.1200/JCO.2005.03.3845, 16145060.
5. Alshareeda AT, Soria D, Garibaldi JM, Rakha E, Nolan C, Ellis IO, Green AR. Characteristics of basal cytokeratin expression in breast cancer. Breast Cancer Res Treat 2013, 139(1):23-37. 10.1007/s10549-013-2518-x, 23588953.
6. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131(1):18-43.
7. Bhurgri Y, Bhurgri A, Nishter S, Ahmed A, Usman A, Pervez S, Ahmed R, Kayani N, Riaz A, Bhurgri H, Bashir I, Hassan SH. Pakistan-Country profile of cancer and cancer control 1995-2004. J Pak Med Assoc 2006, 56(3):124-130.
8. Bhurgri Y, Bhurgri A, Hassan SH, Zaidi SHM, Rahim A, Sankaranarayanan R, Parkin DM. Cancer incidence in Karachi, Pakistan: first results from Karachi cancer registry. Int J Cancer 2000, 85:325-329. 10.1002/(SICI)1097-0215(20000201)85:3<325::AID-IJC5>3.0.CO;2-J, 10652421.
9. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's surveillance, epidemiology, and end results database. Cancer 2007, 110:876. 10.1002/cncr.22836, 17620276.
10. Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE. Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S.-aSEER analysis. BMC Cancer 2010, 10:191. 10.1186/1471-2407-10-191, 2873947, 20459777.
11. Cheng HT, Huang T, Wang W, Yue JQ, Shen N, Guo H, Li DP, Zhao QZ, Yi PF, Wang R, Wang LQ. Clinicopathological features of breast cancer with different molecular subtypes in Chinese women. J Huazhong Univ Sci Technolog Med Sci 2013, 33(1):117-121. 10.1007/s11596-013-1082-2, 23392719.
12. Bhurgri Y, Kayani N, Faridi N, Pervez S, Usman A, Bhurgri H, Malik J, Bashir I, Bhurgri A, Hasan SH, Zaidi SH. Patho-epidemiology of breast cancer in Karachi " 1995-1997" . Asian Pac J Cancer Prev 2007, 8(2):215-220.
13. Hashmi AA, Faridi N, Khurshid A, Naqvi H, Malik B, Malik FR, Fida Z, Mujtuba S. Accuracy of frozen section analysis of sentinel lymph nodes for the detection of Asian breast cancer micrometastasis-experience from Pakistan. Asian Pac J Cancer Prev 2013, 14(4):2657-2662. 10.7314/APJCP.2013.14.4.2657, 23725191.
14. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer. Am J Clin Pathol 2005, 123:16-20. 10.1309/HCF035N9WK40ETJ0, 15762275.
15. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25(1):118-145.
16. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18:1133-1144. 10.1093/annonc/mdm271, 17675394.
17. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329. 10.1093/annonc/mdp322, 2720818, 19535820.
18. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009, 20:1071. doi: 10.1007/s10552-009-9331-1, 10.1007/s10552-009-9331-1, 19343511.
19. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 2011, 103:470. doi: 10.1093/jnci/djr030, 10.1093/jnci/djr030, 3057984, 21346227.
20. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008, 109:123. 10.1007/s10549-007-9632-6, 2443103, 17578664.
21. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W, Buerger H. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002, 82:1525. 10.1097/01.LAB.0000038508.86221.B3, 12429812.
22. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, van Diest PJ, Brandt B, Boecker W, Buerger H. How basal are triple-negative breast cancers?. Int J Cancer 2008, 123:236. doi:10.1002/ijc.23518, 10.1002/ijc.23518, 18398844.
23. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750. doi:10.1172/JCI45014, 10.1172/JCI45014, 3127435, 21633166.
24. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007, 8:R157. 10.1186/gb-2007-8-8-r157, 2374988, 17683518.
25. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68. doi: 10.1186/bcr2635, 10.1186/bcr2635, 3096954, 20813035.
26. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9(5):R65. 10.1186/bcr1771, 2242660, 17910759.
27. Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, Hanby A. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006, 49(1):22-34. 10.1111/j.1365-2559.2006.02453.x, 16842243.
28. Carter MR, Hornick JL, Lester S, Fletcher CD. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol 2006, 30:300-309.
29. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast: IV: squamous cell carcinoma of ductal origin. Cancer 1990, 65:272-276. 10.1002/1097-0142(19900115)65:2<272::AID-CNCR2820650215>3.0.CO;2-6, 2153044.
30. Rosen PP, Ernsberger D. Low-grade adenosquamous carcinoma: a variant of metaplastic mammary carcinoma. Am J Surg Pathol 1987, 11:351-358. 10.1097/00000478-198705000-00003, 3578645.
31. Hanna W, Kahn HJ. Ultrastructural and immunohistochemical characteristics of mucoepidermoid carcinoma of the breast. Hum Pathol 1985, 16:941-946. 10.1016/S0046-8177(85)80133-7, 4029947.
32. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast: V: metaplastic carcinoma with osteoclastic giant cells. Hum Pathol 1990, 21:1142-1150. 10.1016/0046-8177(90)90151-T, 2227922.
33. Sneige N, Yaziji H, Mandavilli SR, Perez ER, Ordonez NG, Gown AM, Ayala A. Low-grade (fibromatosis-like) spindle cell carcinoma of the breast. Am J Surg Pathol 2001, 25:1009-1016. 10.1097/00000478-200108000-00004, 11474284.
34. Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, Pereira EM, Lakhani SR, Schmitt FC. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006, 49:10-21. 10.1111/j.1365-2559.2006.02467.x, 16842242.
35. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J, Debono S, Houvenaeghel G, Maraninchi D, Viens P, Charpin C, Jacquemier J, Birnbaum D. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006, 66:4636-4644. 10.1158/0008-5472.CAN-06-0031, 16651414.
36. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006, 25:127-141. 10.1002/sim.2331, 16217841.
37. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008, 100:207-212. 10.1093/jnci/djm289, 18230798.
38. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 2009, 20(4):628-635. 10.1093/annonc/mdn675, 19074747.
39. Rakha EA, El-Sayed ME, Reis-Filho JS, Ellis IO. Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology 2008, 52:67-81. doi:10.1111/j.1365-2559.2007.02894.x.
40. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800. 10.1056/NEJMra0801289, 19228622.
41. Vallejos CS, Gómez HL, Cruz WR, Pinto JA, Dyer RR, Velarde R, Suazo JF, Neciosup SP, León M, de la Cruz MA, Vigil CE. Breast cancer classification according to immunohistochemistry markers: subtypes and association withclinicopathologic variables in a peruvian hospital database. Clin Breast Cancer 2010, 10(4):294-300. 10.3816/CBC.2010.n.038, 20705562.
42. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010, 25:7(5).
43. Cakir A, Gonul II, Uluoglu O. A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-likecarcinomas. Diagn Pathol 2012, 7:145. 10.1186/1746-1596-7-145, 3488514, 23082819.
44. Cheng H, Qin Y, Fan H, Su P, Zhang X, Zhang H, Zhou G. Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes. Diagn Pathol 2013, 8:129. 10.1186/1746-1596-8-129, 3766166, 23915145.
45. Klingen TA, Chen Y, Suhrke P, Stefansson IM, Gundersen MD, Akslen LA. Expression of thyroid transcription factor-1 is associated with a basal-like phenotype in breast carcinomas. Diagn Pathol 2013, 8:80. 10.1186/1746-1596-8-80, 3658996, 23675755.
46. Liu L, Liu Z, Qu S, Zheng Z, Liu Y, Xie X, Song F. Small breast epithelial mucin tumor tissue expression is associated with increased risk of recurrence and death in triple-negative breast cancer patients. Diagn Pathol 2013, 8:71. 10.1186/1746-1596-8-71, 3680073, 23635316.
47. Svoboda M, Sana J, Redova M, Navratil J, Palacova M, Fabian P, Slaby O, Vyzula R. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol 2012, 7:31. 10.1186/1746-1596-7-31, 3349474, 22439831.
48. Laurinavicius A, Laurinaviciene A, Ostapenko V, Dasevicius D, Jarmalaite S, Lazutka J. Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol 2012, 7:27. 10.1186/1746-1596-7-27, 3319425, 22424533.
49. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006, 295(21):2492-2502. 10.1001/jama.295.21.2492, 16757721.
50. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109(9):1721-1728. 10.1002/cncr.22618, 17387718.
51. Giles GG, English DR. The Melbourne collaborative cohort study. IARC Sci Publ 2002, 156:69-70.
52. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Bégin LR, Hamel N, Goffin JR, Wong N, Trudel M, Kapusta L, Porter P, Akslen LA. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004, 64:830. 10.1158/0008-5472.CAN-03-2970, 14871808.
53. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, Akslen LA. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95:1482. 10.1093/jnci/djg050, 14519755.
54. Olopade OI, Grushko T. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001, 344:2028.